NCT07548099 Molecular Imaging of the Underlying Mechanism of Vessel Wall Inflammation Using Positron Emission Tomography (PET/CT)
| NCT ID | NCT07548099 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Pennsylvania |
| Condition | Abdominal Aortic Aneurysm |
| Study Type | OBSERVATIONAL |
| Enrollment | 30 participants |
| Start Date | 2026-04-30 |
| Primary Completion | 2028-04-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 30 participants in total. It began in 2026-04-30 with a primary completion date of 2028-04-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This research study is being conducted to test how an imaging drug called 64Cu-DOTA-ECL1i can be used to image an abdominal aortic aneurysm. 64Cu-DOTA-ECL1i is a drug used with an imaging test called a PET/CT (Positron Emission Tomography/Computed Tomography). The aim is to collect data using a new imaging drug called 64Cu-DOTA-ECL1i that may be able to create images of inflammation in the aorta, which is thought to be important in how aneurysms grow and develop and to understand how consistent these scans are across time and what might affect the inflammation.
Eligibility Criteria
Inclusion Criteria: 1. Participants will be at least 18 years of age 2. Have an established diagnosis of abdominal aortic aneurysm based on standard clinical criteria or are an age matched control with absence of known AAA. 3. Participants must be informed of the investigational nature of this study and be willing to provide written informed consent and participate in this study in accordance with institutional and federal guidelines prior to study-specific procedures. Exclusion Criteria: 1. Females who are pregnant or breast feeding at the time of the PET/CT scan will not be eligible for this study; a urine pregnancy test will be performed in women of child-bearing potential before the injection of radiotracer. 2. Inability to tolerate imaging procedures in the opinion of an investigator or treating physician 3. Patients with chronic renal disease whose GFR is less than 40 mL/min/1.73m² at the time of enrollment. 4. Documented allergy to iodinated contrast 5. Any current medical condition, illness, or disorder as assessed by medical record review and/or self-reported that is considered by a physician investigator to be a condition that could compromise participant safety or successful participation in the study 6. Less than 6 months life expectancy as deemed by the treating physician at the time of initial enrollment.
Contact & Investigator
Scott M Damrauer, MD
PRINCIPAL INVESTIGATOR
Penn Medicine Division of Vascular Surgery
Frequently Asked Questions
Who can join the NCT07548099 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Abdominal Aortic Aneurysm. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07548099 currently recruiting?
Yes, NCT07548099 is actively recruiting participants. Contact the research team at erin.schubert@pennmedicine.upenn.edu for enrollment information.
Where is the NCT07548099 trial being conducted?
This trial is being conducted at Philadelphia, United States.
Who is sponsoring the NCT07548099 clinical trial?
NCT07548099 is sponsored by University of Pennsylvania. The principal investigator is Scott M Damrauer, MD at Penn Medicine Division of Vascular Surgery. The trial plans to enroll 30 participants.